News
Jardiance filed in Japan for chronic kidney disease
Nippon Boehringer Ingelheim and Eli Lilly Japan said on January 31 that their SGLT2 inhibitor Jardiance (empagliflozin) was filed with Japanese regulatory authorities for an additional indication of chronic kidney disease (CKD)
The submission follows data from the global PIII EMPA-KIDNEY trial, which enrolled 6,609 participants diagnosed with CKD including Japanese. In the study, Jardiance on top of standard of care significantly cut the risk of CKD progression or cardiovascular death by 28% versus placebo.
Condition: Chronic Kidney Disease/CKD
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.